{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:53:57Z","timestamp":1790985237089,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Jinshan Doctor Project","award":["2025-JSYZ-33"],"award-info":[{"award-number":["2025-JSYZ-33"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-05070-3","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:34:15Z","timestamp":1783607655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed death-1 inhibitors in recurrent intermediate and advanced hepatocellular carcinoma: a single-centre retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Wei fan","family":"Sui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu xin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze feng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian hua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"7","key":"5070_CR1","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/cac2.70017","volume":"45","author":"M Li","year":"2025","unstructured":"Li M, Cao S, Xu RH. Global trends and epidemiological shifts in gastrointestinal cancers: insights from the past four decades. Cancer Commun (Lond). 2025;45(7):774\u201388.","journal-title":"Cancer Commun (Lond)"},{"issue":"6","key":"5070_CR2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1159\/000509424","volume":"9","author":"J Zhou","year":"2020","unstructured":"Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver cancer. 2020;9(6):682\u2013720.","journal-title":"Liver cancer"},{"issue":"1","key":"5070_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25\u201334.","journal-title":"Lancet Oncol"},{"issue":"10126","key":"5070_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"3","key":"5070_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"issue":"10088","key":"5070_CR6","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502.","journal-title":"Lancet"},{"issue":"4","key":"5070_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):571\u201380.","journal-title":"Lancet Oncol"},{"issue":"5","key":"5070_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/02841850801958890","volume":"49","author":"B Wang","year":"2008","unstructured":"Wang B, Xu H, Gao ZQ, et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol. 2008;49(5):523\u20139.","journal-title":"Acta Radiol"},{"key":"5070_CR9","doi-asserted-by":"crossref","unstructured":"Pinato DJ, Murray SM, Forner A, et al. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer. 2021;9(9):e003311.","DOI":"10.1136\/jitc-2021-003311"},{"issue":"4","key":"5070_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00270-021-03031-9","volume":"45","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Vogel A, Madoff DC, et al. Randomized phase 3 LEAP-012 study: transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment. Cardiovasc Interv Radiol. 2022;45(4):405\u201312.","journal-title":"Cardiovasc Interv Radiol"},{"issue":"12","key":"5070_CR11","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2217\/fon-2021-1261","volume":"18","author":"NB Khaled","year":"2022","unstructured":"Khaled NB, Seidensticker M, Ricke J, et al. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. Future Oncol. 2022;18(12):1423\u201335.","journal-title":"Future Oncol"},{"issue":"1","key":"5070_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","volume":"8","author":"HD Zhu","year":"2023","unstructured":"Zhu HD, Li HL, Huang MS, et al. Transarterial chemoembolization with PD-(L) 1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Therapy. 2023;8(1):58\u201368.","journal-title":"Signal Transduct Target Therapy"},{"issue":"01","key":"5070_CR13","first-page":"052","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM, Modified. RECIST (mRECIST) assessment for hepatocellular carcinoma[C]\/\/Seminars in liver disease. \u00a9 Thieme Med Publishers. 2010;30(01):052\u201360.","journal-title":"\u00a9 Thieme Med Publishers"},{"issue":"1","key":"5070_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-021-01967-3","volume":"21","author":"Y Han","year":"2021","unstructured":"Han Y, Cao G, Sun B, et al. Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. BMC Gastroenterol. 2021;21(1):1\u201310.","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"5070_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.21147\/j.issn.1000-9604.2024.02.02","volume":"36","author":"Y Ren","year":"2024","unstructured":"Ren Y, Li Y, Cao M, et al. Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma: A single-center, prospective, single-arm clinical trial. Chin J Cancer Res. 2024;36(2):114\u201323.","journal-title":"Chin J Cancer Res"},{"issue":"10474","key":"5070_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","volume":"405","author":"M Kudo","year":"2025","unstructured":"Kudo M, Ren Z, Guo Y, et al. LEAP-012 investigators. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomized, double-blind, phase 3 study. Lancet. 2025;405(10474):203\u201315.","journal-title":"Lancet"},{"issue":"5","key":"5070_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat reviews Gastroenterol Hepatol. 2021;18(5):293\u2013313.","journal-title":"Nat reviews Gastroenterol Hepatol"},{"issue":"3","key":"5070_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","volume":"19","author":"M Ringelhan","year":"2018","unstructured":"Ringelhan M, Pfister D, O\u2019Connor T, et al. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19(3):222\u201332.","journal-title":"Nat Immunol"},{"issue":"10474","key":"5070_CR19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","volume":"405","author":"B Sangro","year":"2025","unstructured":"Sangro B, Kudo M, Qin S, et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2025;405(10474):216\u201332.","journal-title":"Lancet"},{"key":"5070_CR20","doi-asserted-by":"crossref","unstructured":"Zhu HD, Fan WJ, Zhao C, et al. Transarterial chemoembolization combined with camrelizumab and rivoceranib for unresectable hepatocellular carcinoma (CHANCE2005\/CARES-005): a randomized phase II trial. J Clin Oncol. 2026;44(11):959\u201369.","DOI":"10.1200\/JCO-25-01796"},{"key":"5070_CR21","doi-asserted-by":"crossref","unstructured":"Chen JJ, Jin ZC, Zhou JW, et al. Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic agents in intermediate-stage hepatocellular carcinoma (CHANCE2202): a target trial emulation study. EClinicalMedicine. 2026;6(92):103766\u201379.","DOI":"10.1016\/j.eclinm.2026.103766"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05070-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05070-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05070-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:03:20Z","timestamp":1790982200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-05070-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5070"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-05070-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the institutional Ethics Committee of the Affiliated People\u2019s Hospital of Jiangsu University (SQK-2025235-W) and consent to participate was waived by the Ethics Committee due to the retrospective nature of the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"604"}}